Amneal Pharmaceuticals (AMRX) to Release Quarterly Earnings on Friday

Amneal Pharmaceuticals (NASDAQ:AMRX) will be announcing its earnings results before the market opens on Friday, May 3rd. Analysts expect the company to announce earnings of $0.08 per share for the quarter. Amneal Pharmaceuticals has set its FY 2024 guidance at 0.530-0.630 EPS.Persons that wish to listen to the company’s earnings conference call can do so using this link.

Amneal Pharmaceuticals (NASDAQ:AMRX) last posted its earnings results on Friday, March 1st. The company reported $0.12 EPS for the quarter, beating analysts’ consensus estimates of $0.05 by $0.07. Amneal Pharmaceuticals had a positive return on equity of 126.04% and a negative net margin of 3.51%. The company had revenue of $616.98 million for the quarter, compared to the consensus estimate of $630.67 million. On average, analysts expect Amneal Pharmaceuticals to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Amneal Pharmaceuticals Price Performance

NASDAQ:AMRX opened at $6.12 on Thursday. Amneal Pharmaceuticals has a 52 week low of $1.74 and a 52 week high of $6.46. The company has a quick ratio of 0.94, a current ratio of 1.63 and a debt-to-equity ratio of 121.31. The company has a market capitalization of $1.88 billion, a P/E ratio of -19.74 and a beta of 1.33. The stock’s fifty day moving average is $5.73 and its two-hundred day moving average is $5.24.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on AMRX shares. Barclays lifted their price objective on Amneal Pharmaceuticals from $6.00 to $8.00 and gave the company an “overweight” rating in a research note on Monday, January 29th. The Goldman Sachs Group boosted their target price on Amneal Pharmaceuticals from $5.50 to $6.25 and gave the stock a “buy” rating in a research note on Monday, March 4th. StockNews.com cut Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Monday, March 4th. Finally, Piper Sandler boosted their target price on Amneal Pharmaceuticals from $6.00 to $8.00 and gave the stock an “overweight” rating in a research note on Thursday, March 21st. Five research analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $7.31.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.